Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing

Company with Stem Cell in FDA Cleared Phase III COVID-19 Clinical Trial Comments on Scientific Support for Nutraceutical Already on the Market

News provided by

Therapeutic Solutions International

Sep 27, 2021, 09:00 ET

ELK CITY, Idaho, Sept. 27, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI).

On May 5th, 2020, Therapeutic Solutions International publicly announced their production and patent filing's for QuadraMune™, a nutraceutical developed with the aim of naturally modulating susceptibility, immunity, and inflammation in the context of COVID-19¹.

On November 24th, 2020, TSOI announced results of a clinical trial demonstrating in healthy volunteers that QuadraMune™ increases natural killer cell activity². Natural killer cells are believed to be part of the body's "innate" immune response to viral infections such as SARS-CoV-2, the causative agent of COVID-19.

On December 1st, 2020, TSOI reported the results of another clinical trial in which QuadraMune™ was shown to increase interleukin 2, a protein associated with T cell responses³. T cells are considered the "adaptive" arm of the immune system and are needed for creation of immunological memory to prevent re-infections.

Following TSOI's initial research, there have been multiple studies published in peer-reviewed journals by independent academic institutions supporting the individual ingredients in QuadraMune™, which are listed below by ingredients.

To our knowledge, QuadraMune™ is the only nutraceutical on the market with this level of independent scientific support for its potential use in COVID-19.

QuadraMune™ Ingredient #1: Pterostilbene:

- November 11th, 2020. Researchers at the University of Ha'il, Saudi Arabia, used computer modeling to screen 200,000 natural compounds for the ability to block interaction between SARS-CoV2 Spike Protein and ACE2 receptor. They found pterostilbene to be the top 2 blocker of this interaction, which is critical for the virus to infect cells⁴.

- July 10th, 2021. Researchers at the University of Groningen in the Netherlands reported "resveratrol and its metabolically more stable structural analog, pterostilbene, exhibit potent antiviral properties against SARS-CoV-2 in vitro⁵."

QuadraMune Ingredient #2: Thymoquinone:

- July 12th, 2020. Researchers at University of Casablanca, Morocco reported thymoquinone may have inhibitory activities against SARS CoV2 protease. Activity of the protease is needed for the virus to replicate⁶.

- November 3rd, 2020. Scientists at University of Dalian, China, demonstrated thymoquinone prevents kidney damage in a mouse model of systemic inflammation resembling COVID-19⁷.

- March 3rd, 2021. A paper from the Graduate School of Pharmaceutical Sciences in South Korea entitled "Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID-19 prevention and cure" described why thymoquinone, the active ingredient in Nigella Sativa seeds possesses numerous therapeutic properties making it an ideal adjuvant or monotherapy for COVID-19⁸.

- September 6th, 2021. A randomized clinical trial with 173 COVID-19 patients revealed that 62% of patients who received nigella sativa oil (source of thymoquinone) recovered, whereas only 36% recovered who received placebo⁹. The study was a collaboration between multiple hospitals in Saudi Arabia.

QuadraMune Ingredient #3: Epigallocatechin-3-gallate (EGCG)

- Sept 3rd, 2020. Researchers from Yonsei University in South Korea demonstrated EGCG inhibits SARS-CoV-2 proliferation. They demonstrated mechanistically that this process worked through suppression of 3CL-proteins, which the virus uses to generate its protein components after it has infected cells¹⁰. These findings were replicated by two independent groups¹¹,¹².

- April 13th, 2021. A study led by a group of scientists from the Paul-Ehrlich-Institute at the Department of Virology in Germany showed that EGCG suppressed SARS-CoV-2 virus in vitro¹³. This was replicated by independent groups¹⁴,¹⁵.

- August 10th, 2021. Researchers at the Russian Academy of Sciences reported EGCG suppresses original and SARS-CoV-2 variant (mutant) virus replication¹⁶. This data was independently verified¹⁷.

QuadraMune Ingredient #4: Sulforaphane

- March 25th, 2021. Scientists from John Hopkins published that sulforaphane reduces proliferation of SARS-CoV-2 in the laboratory, as well as in mice¹⁸.

- July 8th, 2021. Researchers at University of Ferrara, Italy published that sulforaphane decreases toxic cytokines produced by lung cells in response to parts of the SARS-CoV-1 virus¹⁹.

Timothy Dixon, President and CEO of Therapeutic Solutions International, stated, "the fact that there was no mention of COVID-19 altering activity of any of the QuadraMune™ ingredients prior to our patent filing, and that now these ingredients are being actively investigated as possible therapies speaks volumes about the wisdom of our scientific team and our advisors who have worked tirelessly at developing QuadraMune™, as well as advancing its science. With the rise of the new variants, as well as realization of the problem of "long hauler" pathologies, we believe that there is an increasing need for natural approaches towards this pandemic."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Therapeutic Solutions International Leverages Filed and Issued Intellectual Property to Develop COVID-19 Nutraceutical Candidate: QuadraMune™ | BioSpace
2 QuadraMune™ Synergizes with Metformin to Stimulate Anti-Viral Defenses in Pilot Clinical Trial (prnewswire.com)
3 Therapeutic Solutions International Announces Positive QuadraMune™ Clinical Trial Data (prnewswire.com)
4 Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates | SpringerLink
5 Viruses | Free Full-Text | Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air–Liquid Interface Cultured Human Primary Bronchial Epithelial Cells (mdpi.com)
6 In Silico Investigation of the SARS CoV2 Protease with Thymoquinone, the Major Constituent of <i>Nigella Sativa | Bentham Science (eurekaselect.com)
7 Effect of Thymoquinone on Acute Kidney Injury Induced by Sepsis in BALB/c Mice (hindawi.com)
8 Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID–19 prevention and cure - Islam - 2021 - Phytotherapy Research - Wiley Online Library
9 Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial – ScienceDirect
10 Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2 3CL-Protease In Vitro (hindawi.com)
11 The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease – ScienceDirect
12 Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2 – ScienceDirect
13 The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection | Microbiology Society (microbiologyresearch.org)
14 Epigallocatechin Gallate Inhibits the Uridylate-Specific Endoribonuclease Nsp15 and Efficiently Neutralizes the SARS-CoV-2 Strain | Journal of Agricultural and Food Chemistry (acs.org)
15 Molecules | Free Full-Text | Antiviral Effects of Green Tea EGCG and Its Potential Application against COVID-19 (mdpi.com)
16 EGCG as an anti-SARS-CoV-2 agent: Preventive versus therapeutic potential against original and mutant virus – ScienceDirect
17 Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor | Cell & Bioscience | Full Text (biomedcentral.com)
18 Sulforaphane exhibits in vitro and in vivo antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses | bioRxiv
19 Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein - ScienceDirect